Institute of Urology, Second Hospital, Lanzhou University, Gansu, China.
Aging Male. 2010 Jun;13(2):82-6. doi: 10.3109/13685530903406789.
To evaluate the effectiveness of sildenafil versus continuous positive airway pressure (CPAP) for patients with erectile dysfunction (ED) and obstructive sleep apnea (OSA).
This is a meta-analysis of a randomized controlled trial. The main outcome measures for effectiveness were the percentage of successful intercourse attempts, International Index of Erectile Function (IIEF) domain scores (erectile function, EF) and the satisfaction levels of the patients and their partners with the treatment for ED.
Two randomized controlled trials totaling 70 patients were included. Meta-analysis results are as follows: after 12 weeks of treatment, patients under sildenafil demonstrated a significant advantage over under CPAP in terms of the percentage of successful intercourse attempts [OR = 3.24, 95% CI (2.37-4.43)], EF scores [WMD = 3.57, 95%CI (1.68-5.45)], and the satisfaction levels of the patients and their partners with the treatment for ED [OR = 3.56, 95% CI (1.27-9.98)].
Current clinical studies might confirm that both therapeutic methods were safe and effective, but sildenafil was superior to CPAP in the treatment of ED in men with OSA. We conclude that new therapeutic agents or a combination of the two methods should be studied further.
评估西地那非与持续气道正压通气（CPAP）治疗勃起功能障碍（ED）合并阻塞性睡眠呼吸暂停（OSA）患者的有效性。
这是一项随机对照试验的荟萃分析。有效性的主要结局指标为成功性交尝试的百分比、国际勃起功能指数（IIEF）各域评分（勃起功能，EF）以及患者及其伴侣对 ED 治疗的满意度。
纳入了两项共 70 例患者的随机对照试验。荟萃分析结果如下：治疗 12 周后，西地那非组患者在成功性交尝试的百分比[OR=3.24，95%CI（2.37-4.43）]、EF 评分[WMD=3.57，95%CI（1.68-5.45）]和患者及其伴侣对 ED 治疗的满意度[OR=3.56，95%CI（1.27-9.98）]方面均显著优于 CPAP 组。
目前的临床研究可能证实，这两种治疗方法均安全有效，但西地那非在治疗 OSA 合并 ED 的男性患者方面优于 CPAP。我们认为应进一步研究新的治疗药物或两种方法的联合应用。
